On August 6, 2015 Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or the "Company"), reported its results of operations and financial condition for the second quarter ended June 30, 2015 (Filing, 8-K, Provectus Pharmaceuticals, AUG 6, 2015, View Source [SID:1234507050]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Provectus will also hold its quarterly business update conference call at 4 p.m. (EDT) today to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337, approximately 15 minutes before the call. A webcast will also be available at: www.pvct.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until September 30, 2015 and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, and using the Conference ID#13614501.

Second Quarter Financial Results and Balance Sheet Highlights

The Company’s cash and cash equivalents were $23,117,144 at June 30, 2015, compared with $17,391,601 at December 31, 2014.

Therefore, the Company’s ability to continue as a going concern is reasonably assured due to its cash and cash equivalents on hand at June 30, 2015. Given the Company’s current rate of expenditures and its ability to curtail or defer certain controllable expenditures, the Company has sufficient cash on hand to last well into 2017.

Stockholders’ equity at June 30, 2015, was $30,246,789. This compares to stockholders’ equity at December 31, 2014, of $25,189,876.

For additional information regarding Provectus’ results of operations and financial condition for the second quarter ended June 30, 2015, please see Provectus’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2015.